Developing Innovative New Therapies to Help Patients
Types of Diseases Verismo Targets
Verismo is currently developing CAR T cell candidates with our SynKIR™ platform that target different indications in patients.
Solid Tumors
- Ovarian Cancer
- Mesothelioma
- Cholangiocarcinoma
Blood Cancers (post-CAR relapsed/refractory and CAR-naive)
- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Other B-Cell Non-Hodgkin Lymphomas
What Is CAR T Cell Therapy?
CAR T cell therapy is a type of treatment in which a patient’s own T cells (white blood cells that are part of the immune system) are collected from a patient’s blood and genetically modified in a laboratory to recognize specific disease-causing cells, such as tumors. These modified T cells are called Chimeric Antigen Receptor (CAR) T cells. When the CAR T cells are infused back into the patient, they recognize and destroy the targeted disease-causing cells using the T cell’s natural function.
The Challenges for Current CAR T Cell Therapies
CAR T cells based on a single-chain design can become exhausted when attacking their tumor targets, making potential treatments either short-lived or ineffective.
That’s why Verismo Therapeutics has developed a new type of dual-chain CAR T cell technology, called SynKIR™, that has the potential to reduce T cell exhaustion allowing for prolonged SynKIR™ T cell function.
What Makes Verismo’s SynKIR CAR T Cell Platform Unique?
Verismo’s SynKIR™ is a CAR T cell therapy that uses a novel, nature-inspired technology to switch on and off. When in the presence of its target, SynKIR™ will switch on the T cell to attack the targeted tumor cell; when the target cell is not present, SynKIR™ switches off to rest and recover to fight the next time. This more natural cycling of on and off has the potential to translate to longer-lasting CAR T function and disease remissions in patients being treated with SynKIR™.
Current Clinical Trials
STAR-101 for Mesothelin-Expressing Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
This first-in-human (FIH) Phase I trial is designed to assess the safety, feasibility, and potential anti-tumor activity of a single intravenous (IV) dose of SynKIR™-110 administered to patients with advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Status: Recruiting
For more information, please visit: https://clinicaltrials.gov/study/NCT05568680
CELESTIAL-301 for Post-CAR Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
This FIH Phase 1 trial is designed to assess the safety, tolerability, and preliminary efficacy of a single intravenous (IV) dose of SynKIR™-310 administered to subjects with relapsed/refractory (r/r) B-cell Non-Hodgkin Lymphomas (B-cell NHL), including Diffuse Large B-Cell lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL). The study will enroll patients who previously received CAR T therapy but who are refractory or have since relapsed as well as those who have not received CAR T therapy.
Status: Recruiting
For more information, please visit: https://clinicaltrials.gov/study/NCT06544265
Compassionate Use Policy
We understand that in some cases, when it is not possible for a patient to participate in a clinical trial, the patient’s physician may seek access to Verismo investigational drugs outside of the clinical trial setting. These situations are often referred to as “managed access,” “expanded access,” “early access,” “preapproval access,” “compassionate use,” or “emergency use.”
At our current early stage of drug development and clinical trials, Verismo is not making its investigational drugs available on a compassionate use basis. However, this policy will be reviewed and reassessed as our trials progress.
If you have any questions about Verismo’s Expanded Access Policy or would like to make a request for expanded access, please contact expanded-access@verismotherapeutics.com. Verismo anticipates acknowledging receipt of any expanded access questions or requests within five business days of receipt. In the event that Verismo decides to consider expanded access requests for its investigational drugs in the future, Verismo will evaluate and respond to each expanded access request on a case-by-case basis. In the event that Verismo decides to make its investigational products available on an expanded access basis, this policy will be updated with a hyperlink to the relevant expanded access record(s) on clinicaltrials.gov after such records become active.
Verismo developed this expanded access policy and made this policy available in compliance with the 21st Century Cures Act. Verismo may revise this expanded access policy at any time, and the posting of this policy by Verismo does not serve as a guarantee of access to any specific investigational drug by any individual patient.